Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

SPEED Enrollment Guide for Federally Qualified Health Centers

SPEED Program Overview:

The Special Projects for Equitable and Efficient Distribution (SPEED) of the COVID-19 outpatient therapeutics (i.e., monoclonal antibodies [mAbs]) program provides targeted outreach to and engagement with priority settings that care for populations at high risk for hospitalization. The four priority settings supported by SPEED are: long-term care facilities (LTCF), dialysis centers, federally qualified health centers (FQHCs), and correctional facilities. Any FQHC or look-alike with the capacity and capability to administer mAbs to their patients is eligible to participate in SPEED. FQHCs that do not have on-site capabilities to administer mAbs are encouraged to partner with local hospitals or community infusion centers.

Key Resources:

mAb Administration Baseball Cards:

Administration playbooks:

Reimbursement information:

General guidance:

More information

Ordering Product

All sites that meet the requirements for administering monoclonal antibody therapeutics must order casirivimab/imdevimab, bamlanivimab/etesevimab, and etesevimab only directly from AmerisourceBergen Corporation (ABC), the drugs’ sole distributor. The products remain free of charge to requesting sites. To learn more, see the direct ordering process guide and place orders directly with ABC using the C19 Therapies Direct Order Request system.

Tracking Utilization

All sites that use monoclonal antibody therapeutics are required to report on utilization of the product every Wednesday. To learn more about your facility’s reporting requirements, see the process for tracking utilization of COVID-19 therapeutics.

Special Projects for Equitable and Efficient Distribution (SPEED)

COVID-19 Monoclonal Antibody Therapeutics

​Special Projects for Equitable and Efficient Distribution (SPEED)

COVID-19 Monoclonal Antibody Therapeutics

  • This page last reviewed: April 16, 2021